Corbus Pharmaceuticals, Inc. is a biopharmaceutical company based in Norwood, MA, dedicated to developing innovative scientific approaches to combat serious illnesses. Their pipeline includes a next-generation Nectin-4 Antibody Drug Conjugate (ADC) and monoclonal antibodies that target integrins to inhibit the activation of TGF. With a commitment to connecting innovation to purpose, Corbus Pharmaceuticals aims to help people overcome serious diseases.
Driven by a team of high-achieving, innovative, and passionate individuals, Corbus Pharmaceuticals is focused on bringing novel scientific solutions to well-understood biological pathways in the field of oncology. Their dedication to advancing medical research is evident through their recent FDA clearance of an IND application for their anti-v-8 monoclonal antibody CRB-601 and the acceptance of an abstract for presentation at the 2024 ASCO GU conference.
Generated from the website